- AdventHealth
AdventHealth has been invited to play a pivotal role in advancing responsible AI within the health care industry.
ORLANDO, Fla., April 17, 2024 — AdventHealth has been asked to participate in two critical initiatives focused on the responsible development and implementation of artificial intelligence (AI) in health care, highlighting the recognition of the health system’s expertise and thought leadership in the field.
“AdventHealth is honored to be part of a selected group of organizations leading the national conversation on the responsible use of AI in health care,” said Dr. Victor Herrera, chief clinical officer for AdventHealth’s Central Florida Division. “We value the opportunity to share our knowledge and experience in using artificial intelligence to provide whole-person care.”
AdventHealth is using AI in many ways, each one of which has been reviewed and approved by an advisory board which takes patient safety and privacy into account before approving technology for use. The board includes top health care professionals along with industry experts to help vet each program before it’s put into use with patients.
The initiatives are:
Coalition for Health AI (CHAI)
AdventHealth is a founding member of the Coalition for Health AI (CHAI), a group shaping the responsible use of AI in health care. CHAI unites leading health care providers, technology companies, and academic institutions to establish best practices for AI development and implementation. Their working groups focus on safety, transparency and accountability in all AI applications. Both the Food & Drug Administration, as well as the Office of the National Coordinator for Health Information Technology – which is within the U.S. Department of Health and Human Services – are also involved in the leadership of CHAI.
Along with AdventHealth, CHAI’s members include Johns Hopkins Medicine and Mayo Clinic as well as Amazon, Google and Microsoft.
Trustworthy, Responsible AI Network (TRAIN)
Another founding member role finds AdventHealth collaborating with the Trustworthy, Responsible AI Network (TRAIN). This consortium of health care leaders strives to make safe and effective AI accessible to every health care organization. TRAIN will facilitate the sharing of best practices, develop tools to measure AI effectiveness in health care and create a registry for sharing information on AI algorithms as well as operationalizing responsible AI principles recommended by CHAI.
AdventHealth is joined by Microsoft in collaborating with TRAIN, along with Duke Health, Cleveland Clinic and Boston Children's Hospital.
“By sharing our knowledge and collaborating with other health care leaders through CHAI and TRAIN, we can significantly accelerate the development of AI solutions that will improve patient outcomes and shape the future of health care,” said Rob Purinton, vice president of analytics and performance improvement for AdventHealth, who, along with Herrera, underscores that AI will augment, not replace, health care professionals.
“These tools will help caregivers be more effective and efficient while improving their experience when taking care of patients,” Purinton said.
Recent News
AdventHealth Cancer Institute Advances the Use of CAR T-Cell Therapy for Multiple Myeloma
CAR-T therapies have emerged as new treatment options for certain types of cancer through a one-time infusion that can lead to long-lasting remission.
AdventHealth Graduate Medical Education Program Celebrates 50 Years
Growing from a family practice residency to 24 accredited programs, AdventHealth’s Graduate Medical Education (GME) program celebrates 50 years.
New Clinical Trial Explores Digital Intervention for Apathy in Late-life Depression
Afflicting 30-50% of patients with late-life depression, apathy is a challenging psychiatric syndrome in older adulthood that can result in lack of motivation leading to poor self-care, physical...
AdventHealth Performs Central Florida’s First Liver Transplant for Unresectable Colorectal Liver Metastases
In June 2025, AdventHealth Abdominal Transplant Surgeon and Surgical Oncologist Ryan Day, MD, worked with a multidisciplinary team to perform Central Florida’s first liver transplant for unresectable...
AdventHealth Neuroscience Institute First in Florida to be Recognized as a GammaTile Center of Excellence
GammaTile is the first and only tile-based radiation therapy for the treatment of
operable brain tumors. The AdventHealth Neuroscience Institute began performing GammaTile procedures in 2021 and was...
An AdventHealth Collaboration Explores the Impact of Microgravity and Electrical Stimulation on Muscle Cell Health in Space
Using a muscle lab-on-chip model aboard the International Space Station (ISS), AdventHealth Translational Research Institute’s Dr. Paul Coen has been working with a multidisciplinary team from the...
AdventHealth Neuroscience Institute Among First in U.S. to Offer Phase IIa Clinical Trial of Troculeucel for Moderate Alzheimer’s Disease
While most clinical trials for Alzheimer’s disease have focused on patients with early or mild cognitive impairment, roughly 30% of those with Alzheimer’s have moderate stage disease for which there...
AdventHealth Translational Research Institute Selected as Clinical Site for National Study of Muscle, Mobility and Aging (SOMMA)
Under the leadership of Scientific Director and Principal Investigator Bret H. Goodpaster, PhD, the AdventHealth Translational Research Institute (TRI) is now enrolling men and women 70 years of age...
AdventHealth Neuroscience Institute Administers First Dose of Investigative NK Cell Therapy to Person with Alzheimer’s Disease
Under a single compassionate use Investigational New Drug (IND) authorization cleared by the U.S. Food and Drug Administration (FDA), the AdventHealth Neuroscience Institute worked with NKGen Biotech...
New Study Published in the New England Journal of Medicine Shows the Addition of Regional Nodal Irradiation Does Not Decrease Rate of Invasive Breast Cancer Recurrence in Patients with Negative Axillary Nodes Following Neoadjuvant Chemotherapy
Findings of the phase III, multicenter, randomized NSABP B-51-RTOG 1304 clinical trial were recently published in the New England Journal of Medicine with AdventHealth Cancer Institute’s Dr. Mamounas...
AdventHealth Study Exploring the Use of MR-Guided Focused Ultrasound (MRgFUS) to Disrupt the Blood-Brain Barrier for Treatment of Alzheimer’s Disease
Under the leadership of Dr. Valeria Baldivieso and Dr. Chandan Reddy, the AdventHealth Research Institute is the first and only site in Orlando offering the Exablate Blood-Brain Barrier (BBB)...
AdventHealth Research Institute Offers Phase II Clinical Trial of Etanercept for Treatment of Blast-Induced Tinnitus
Approximately 1 billion people throughout the world suffer from tinnitus (ringing in the ears), and it is the number one disability of those who serve in the U.S. military. The condition can disrupt...